首页 | 本学科首页   官方微博 | 高级检索  
     

受体酪氨酸激酶AXL在肿瘤中的研究进展
引用本文:唐小崧. 受体酪氨酸激酶AXL在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 0(3): 281-284. DOI: 10.11904/j.issn.1002-3070.2017.03.019
作者姓名:唐小崧
作者单位:哈尔滨医科大学附属肿瘤医院内一科 哈尔滨150081
摘    要:AXL是TAM受体酪氨酸激酶家族中的一员,AXL已经被证实与肺癌、乳腺癌、甲状腺癌、前列腺癌和胰腺癌等多种癌症有关.最新证据显示,AXL可促进多种肿瘤的生长、侵袭、转移,其抑制剂可抑制肿瘤形成,这说明AXL可能成为抗肿瘤治疗的潜在靶点,AXL激酶抑制剂的应用可能成为抗肿瘤治疗的新策略.本文对AXL与肿瘤方向的研究进展做一综述.

关 键 词:受体酪氨酸激酶  AXL  肿瘤  ALX激酶抑制剂

Research progress of receptor tyrosine kinase AXL in tumor
Abstract:AXL is a member of the TAM receptor tyrosine kinase family,and AXL has been shown to beassociated with a variety of cancers such as lung cancer,breast cancer,thyroid cancer,prostate cancer and pancre-atic cancer.The latest evidence suggests that AXL can promote the growth,invasion and metastasis of varioustumors,and its inhibitors can also inhibit tumor formation,suggesting that AXL may be a potential target for anti-tumor therapy,and the use of AXL kinase inhibitors may become the new strategy of anti-tumor therapy.This ar-ticle reviews the progress of AXL and tumor.
Keywords:Receptor tyrosine kinase  AXL  Tumor  AXL kinase inhibitors
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号